论文部分内容阅读
1 文献来源rnPaik PK,Felip E,Veillon R,et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations[J]. N Engl J Med,2020,383 (10):931-943.rn2 证据水平rn2b.rn3 背 景rn约3％～4％非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者具有MET 14外显子跳读突变.Tepotinib是高选择性口服MET抑制剂,既往研究表明,tepotinib在MET驱动的肿瘤患者中已显示出令人鼓舞的临床活性.